A Multicenter, Double-blind and Open Label, 4 Year Extension Study of Subcutaneous Secukinumab in Prefilled Syringes, Assessing Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Treated With Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Acronyms SCULPTURE
- Sponsors Novartis; Novartis Pharma KK; Novartis Pharmaceuticals
- 15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 16 Feb 2018 Results presented in a Novartis Media Release.
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.